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Abstract
Background: Even though it has been suggested that antiretroviral therapy has an impact on severe
hypovitaminosis D (SHD) in HIV infected patients, it could be speculated that the different levels of residual
inflammation on HAART (Highly Active Anti Retroviral Therapy) could contribute to SHD and aggravate bone
catabolism in these patients.
Methods: A cross-sectional study was carried out in an unselected cohort of 263 HIV infected outpatients
consulting during Spring 2010. Clinical examinations were performed and medical history, food habits, sun
exposure and addictions were collected. Fasting blood samples were taken for immunological, virological,
inflammation, endocrine and bone markers evaluations.
Results: Ninety-five (36%) patients had SHD. In univariate analysis, a significant and positive association was found
between SHD and IL6 (p = 0.001), hsCRP (p = 0.04), increased serum C-Telopeptides X (CTX) (p = 0.005) and
Parathyroid Hormon (PTH) (p < 0.0001) levels. In multivariate analysis, SHD deficiency correlated significantly with
increased IL-6, high serum CTX levels, lower mean daily exposure to the sun, current or past smoking, hepatitis C,
and functional status (falls), but not with the time spent on the current HAART (by specific drug or overall).
Conclusions: SHD is frequent and correlates with inflammation in HIV infected patients. Since SHD is also
associated with falls and increased bone catabolism, it may be of interest to take into account not only the type of
antiretroviral therapy but also the residual inflammation on HAART in order to assess functional and bone risks. This
finding also suggests that vitamin D supplementation may be beneficial in these HIV-infected patients.
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Background
There is growing evidence that 25 OH vitamin D3 defi-
ciency is highly prevalent in HIV-infected patients, and
induces a number of clinical consequences [1-4]. Low
serum 25-OHD3 concentrations induce bone disorders
like osteomalacia, are associated with increased bone re-
sorption due to secondary hyperparathyroidism, and in-
crease the risks of falls and vertebral and hip fractures
[5]. Vitamin D deficiency is also associated with an
increased risk of cardio metabolic disorders, infectious
diseases and mortality, particularly in HIV-infected
patients [6]. The risk factors of hypovitaminosis D in
HIV infected patients are: a precarious social situation,
high alcohol intake, coinfection with viral hepatitis, and/
or a renal hydroxylation defect [7]. The impact of anti-
retroviral therapy (ARV) has also been raised, but the
role of antiretroviral therapy on bone catabolism
remains controversial [8-11].
While there is growing evidence that certain antiretro-
viral drugs affect vitamin D metabolism by increasing 25
OH vitamin D3 catabolism for efavirenz, or inhibiting
renal hydroxylation of vitamin D for protease inhibitors
(PIs), for example, all the potential mechanisms and
their relevance remains unclear. On the other hand, it
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has been shown that inflammation markers (such as
interleukin-6 (IL6) and highly-sensitive C-Reactive Pro-
tein (hsCRP)) correlated significantly with morbidity in
patients on ARV [12,13]. It could thus be speculated that
the different levels of residual inflammation on ARV
could contribute to hypovitaminosis D and aggravate
bone catabolism in HIV infected patients.
Methods
Since no direct studies have been conducted yet, we car-
ried out a cross-sectional study in an unselected cohort
of 263 HIV infected outpatients consulting during
Spring (March-June) 2010. This research was carried out
in compliance with the Declaration of Helsinki. All of
the patients included provided written informed consent
to specifically participate to this study. According to
current French research guidelines, no additional and
specific ethical approval was needed since blood sam-
pling was performed as part of the usual care in a single
center without additional visit or sampling. All of the
patients underwent a clinical examination, in particular
to determine body mass index, Karnofsky’s index and to
screen for lipodystrophy, and data on their medical his-
tory, food habits, sun exposure and addictions were col-
lected. In particular, the immunological and virological
efficacy and the type of past and present antiretroviral
therapy were collected. In addition, the following data
were systematically collected for each patient via a stan-
dardized questionnaire: present or past addiction,
present and past personal and family history of bone
fractures, endocrine disorders, chronic inflammatory dis-
eases (enterocolopathy, inflammatory arthritis, cirrhosis,
asthma and chronic obstructive pulmonary disease),
treatments (in particular systemic glucocorticoids, and
hormone therapy), functional status (history of falls dur-
ing the previous year), age at menopause and amenor-
rhea for women, and orchidectomy for men. Sun
exposure (expressed as minutes per day) was evaluated
by the patients themselves. The daily intake of calcium
was assessed using the questionnaire recommended by
the French Research and Information Group on Osteo-
porosis (GRIO) [14]. Daily intake of alcohol was consid-
ered “excessive” when above 20 g per day in women and
30 g per day in men.
Fasting blood samples were taken from patients as part
of standard care for immunological, virological, inflam-
mation, endocrine and bone markers evaluations. Serum
25 OH vitamin D3 levels were measured by High Per-
formance Liquid Chromatography (HPLC) coupled with
fluorometry. Plasma total calcium, phosphorus, albumin
and thyroid stimulating hormone (TSH) were quantified
on a Vista analyzer (Siemens Healthcare Diagnostics,
Erlangen, Germany) with dedicated reagents. A severe
deficiency in 25 OH vitamin D3 was defined as a blood
level below 10 ng/ml [25 nmol/l], by contrast with mod-
erate deficiency (between 10 and 30 ng/ml) and normal
levels (above 30 ng/ml – 75 nmol/l). Ionized calcium
was measured on an ABL 800 analyzer (Radiometer,
Bronshoj, Denmark). Serum PTH (Parathyroid hormon)
was quantified on an Immulite 2500 analyzer (Siemens
Healthcare Diagnostics, Erlangern, Germany) with dedi-
cated reagents. Serum C-telopeptides X (CTX) were
quantified using an ELISA kit (IDS Immunodiagnostic
systems, France). The normal serum CTX value was
defined according to sex and age (normal range in men:
0.115 -0.748 ng/ml, in pre-menopausal women: 0.112-
0.738 ng/ml, and in menopausal women: 0.142 - 1.351
ng/ml). Inflammation was assessed by the measurement
of hsCRP (immunonephelemetry on a VISTA analyzer,
Siemens Healthcare Diagnostics, Erlangen, Germany)
and IL6 (using the ultra sensitive ELISA kit, R&D Sys-
tem, Minneapolis, Minn, US).
Patients with severe deficiency were compared with
those with moderate deficiency and those with normal
levels. Categorical variables were compared using Fish-
er’s exact and chi-square tests, and continuous variables
using the analysis of variance or the Mann–Whitney test
when appropriate. Correlations between 25-OHD3 vita-
min D levels and bone and inflammation markers were
also analyzed by linear regression. In the second step,
the patients with severe deficiency were compared with
the others. A backward step-by-step logistic regression
was then conducted for multivariate analysis of the fac-
tors associated with severe 25 OH vitamin D3 deficiency
(dependent variables), including all of the factors asso-
ciated in univariate analysis with a p value of less than
0.20. All of the tests were two-sided and a final p-value
of less than 0.05 was considered statistically significant.
All statistical analyses were performed using StatViewW
version 5.0.
Results
The median age of the patients included was 47.7 years
(range 20–72 years), and 188 (71.5%) were male. BMI
was lower than 19 kg/m2 in 27 patients (10.2%) and
higher than 25 kg/m2 in 83 patients (31.4%). Among the
75 women included, 33 (44%) were post-menopausal,
and four were not menopausal, but suffering from
amenorrhea. Twenty patients (7.6%) had a family history
of hip fracture and 104 (39.5%) patients had a personal
history of fracture: 15 had fragility fracture(s) (6.5%), and
82 had traumatic fracture(s) (35.7%) (undetermined in 7
patients). Long-term corticosteroid treatment was on-
going in 22 (8%) patients. Fifty-three patients were suf-
fering from a chronic disease, including two cases of
inflammatory rheumatic diseases, two cases of enteroco-
lopathy, 23 cases of liver cirrhosis, and 24 cases of
chronic bronchitis. Mean daily calcium intake was 760
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(+/− 356) mg per day, and 149 (57%) patients had cal-
cium intakes below 800 mg per day. Excessive alcohol
consumption was reported in 86 (32%) cases.
The main current and past characteristics of HIV in-
fection and antiretroviral therapy are presented in
Table 1. The time since the HIV diagnosis was 13 years
(+/− 8 years). Patients had very often been followed for
several years and nearly one third of them (33.1%) had
experienced AIDS defining illness. Most of them (91.6%)
were on antiretroviral therapy, with a significant im-
mune response, since the mean CD4 level at inclusion
was 551 +/− 271/mm3, with a mean CD4 nadir of 198
+/− 190/mm3, and 207 (78.7%) patients had an un-
detectable viral load (<50 copies/ml).
Ninety-five (36%) patients had SHD (Table 2). In uni-
variate analysis, age, ethnicity, functional status (Kar-
nofsky’s index and history of falls), daily sun exposure,
tobacco use and hepatitis C coinfection were associated
with SHD. The estimated duration of the HIV infection
was also associated with hypovitaminosis D (p = 0.0008),
whereas the HIV CDC stage, current and nadir CD4,
HIV viral load, and time spent on the current ARV (by
specific drug or overall), and the duration with undetect-
able HIV viral load were not.
A significant and positive association was also found
between SHD and IL6 (p = 0.002), hsCRP (p = 0.12),
increased serum C-Telopeptides X (CTX) (p = 0.05) and
PTH (p < 0.0001) levels (Table 3). In univariate linear re-
gression analysis, 25 OH vitamin D levels were found to
correlate negatively with IL-6 levels (r = 0.14, p = 0.02,
Figure 1A) and also tended to correlate negatively with
serum CTX (r = 0.1, p = 0.10, Figure 1B), but not with
hsCRP.
In multivariate analysis (Table 4), SHD deficiency
remained significantly correlated with increased IL-6,
but also with serum CTX levels above the normal value,
lower mean daily exposure to the sun, current or past
smoking, hepatitis C coinfection, and functional status.
CTX levels expressed as quantitative values did not
modify these results and remained significantly asso-
ciated with SHD (OR +1 ng/ml, 1.96, 95% CI: 1.10-3.50,
p = 0.02).
Discussion
In keeping with previous studies [1], vitamin D defi-
ciency was highly prevalent in HIV-infected patients
(close to 90% in our study cohort), with a prevalence of
SHD ranging between 10 and 50% according to the
places and the seasons [1,8,15-17]. However, the associ-
ation with antiretroviral therapy appeared limited in our
study, despite a significant number of patients on efavir-
enz, PIs and/or tenofovir. The first explanation could be
Table 1 HIV-related characteristics of the 263 patients included
Time elapsed since HIV diagnosis (years), mean +/− SD 13 +/− 8
CDC stage A, n (%) 101 (38.4)
CDC stage B, n (%) 75 (28.5)
CDC stage C, n (%) 87 (33.1)
Karnofsky’s index %, mean +/− SD 92 +/− 14
Time spent on NRTI (months), mean +/− SD 95 +/− 71
Time spent on tenofovir (months), mean +/− SD 25 +/− 27
Time spent on NNRTI (months), mean +/− SD 40 +/− 47
Time spent on PI (months), mean +/− SD 44 +/− 47
Without current antiretroviral therapy, n (%) 22 (8.4)
On HAART including NTI, n (%) 210 (80.5)
On HAART including tenofovir, n (%) 164 (62.8)
On HAART including NNTI, n (%) 92 (35.4)
On HAART including PI, n (%) 151 (57.9)
On HAART including II, n (%) 21 (8.0)
CD4 nadir (/mm3), mean +/− SD 198 +/− 190
Time spent with undetectable HIV viral load (months), mean +/− SD 58 +/− 45
Current CD4 (/mm3), mean +/− SD 551 +/− 271
Current CD8 (/mm3), mean +/− SD 810 +/− 420
Current CD4/CD8 ratio, mean +/− SD 0.80 +/− 0.49
Current undetectable HIV viral load, n (%) 207 (78.7%)
Current HIV viral load (when detectable), log10 copies/ml +/− SD 3.1 +/− 1.2
SD: standard deviation; HAART: Highly Active AntiRetroviral Therapy; NRTI: nucleoside reverse transciptase inhibitor; NNRTI: non nucleoside reverse transciptase
inhibitor; PI: protease inhibitor; II: integrase inhibitor.
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Table 2 Associations between vitamin D status and clinical and therapeutic characteristics (univariate analysis) – only associated factors with a p value < 0.20
are shown in this table
All patients Severe 25-(OH) vitamin D3
deficiency (<10ng/ml)
Moderate 25-(OH) vitamin D3
deficiency (10–30 ng/ml)
25-(OH) Vitamin D3 >30 ng/ml p value
N = 263 N = 95 (36%) N = 135 (51%) N = 33 (13%)
Sex M, n (%) 188 (72%) 75 (79%) 89 (66%) 24 (69%) 0.10
F, n (%) 75 (28%) 20 (21%) 46 (34%) 9 (31%)
Age (years) mean +/− SD 48 +/− 10 49 +/−9 46 +/−10 51 +/−12 0.03
Ethnicity non-African origin, n (%) 230 (87%) 87 (92%) 112 (83%) 31 (94%) 0.07
African origin, n (%) 33 (13%) 8 (8%) 23 (17%) 2 (6%)
Past history of falls, n (%) 120 (46%) 53 (57%) 55 (41%) 12 (36%) 0.03
Co-infections Positive HBs antigenemia 14 (5.3%) 8 (8%) 6 (4%) 0 (0%) 0.14
Positive HCV serology, n (%) 57 (22%) 33 (35%) 18 (14%) 6 (18%) 0.12
Past smokers, n (%) 52 (20%) 20 (21%) 25 (19%) 7 (21%) 0.003
Active smokers, n (%) 120 (46%) 55 (59%) 50 (37%) 14 (45%) 0.003
Sun exposure (min),mean +/− SD 106 +/− 114 93 +/− 108 102 +/− 111 157 +/− 132 0.02
Length of HIV infection (yrs), mean +/−SD 13 +/− 8 16 +/−8 12 +/−7 12 +/−8 0.0008
NRTI exposure (months), mean +/− SD 95 +/− 71 108 +/−70 89 +/−69 84 +/−73 0.08
Lipodystrophy, n (%) 65 (25%) 29 (31%) 31 (23%) 5 (15%) 0.005
Karnofsky’s Index (%), mean +/− SD 92 +/− 14 89 +/−17 92 +/−17 97+/−7 0.008





















that, by contrast with most previous studies, we also
adjusted for the season (since blood samples were exclu-
sively collected in spring 2010, at a time when vitamin D
is synthesized). Sun exposure was found to correlate
positively with vitamin D levels, and each additional one
hour per day of exposure was associated with a signifi-
cant reduction in the OR of SHD (0.84), which is con-
sistent with previous data in non-HIV individuals.
Another explanation is suggested by the highly significant
association between vitamin D levels and inflammation
parameters we observed, which to date has never been
reported. It can thus be suggested that HIV therapy could
have an ambiguous impact on vitamin D levels. By reducing
HIV viral replication and inflammation, ARV is likely to
have a positive impact on vitamin D levels, which is coun-
terbalanced by the potential direct negative effect of some
drugs. We did not observe a statistically significant direct
correlation between HIV viral load and inflammation bio-
markers (data not shown). This association with inflamma-
tion, which has also been recently observed in non HIV
infected patients [18-20], could also partly explain the
increased risk of cardio-metabolic disorders associated with
hypovitaminosis D, since hsCRP and IL6 have also been
shown to be predictors of cardio-vascular and HIV disease
progression and mortality [12,13,16].
Another result of interest is the association between
vitamin D levels, inflammation and bone catabolism (in
particular bone turnover markers CTX and PTH). CTX
corresponds to the serum fraction of collagen called C
telopeptid X, which is associated with osteoclast bone
resorption. By contrast with the results from other study
in HIV-infected patients, in our study, ionized calcium
in the serum stayed within the normal range despite the
vitamin D deficiency, suggesting an adaptive response to
parathyroid hormone [1]. Even though we found a statis-
tically significant association between SHD and inflam-
mation and between SHD and increased bone
catabolism, but not between inflammation and bone ca-
tabolism, the respective weights of hypovitaminosis D
and inflammation in the increase in bone catabolism
cannot be definitely and clearly established.
In addition, an association between SHD and a history
of falls, which has never been reported in HIV-infected
patients, was also observed in the present study. This
proportion of patients with a history of falls is quite
high, considering the median age of our study popula-
tion. It may be partially due to the other characteristics
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Figure 1 A and B: correlations between 25OH vitamin D3 levels
and IL-6 (1A) or C-telopeptide X (1B).






















0.49 (0.31-0.92) 0.45 (0.31-0.70) 0.33 (0.22-0.60) 0.05
High serum CTX, n (%) 56 (21%) 29 (32%) 24 (18%) 3 (9%) 0.01
Serum intact parathyroid
hormone > 65 ng/l, n (%)












2.0 (0.7-6.3) 1.7 (0.6-3.6) 1.6 (1.0-3.8) 0.002
hsCRP: highly-sensitive C-Reactive Protein; IL6: Interleukin 6; High serum CTX = C Telopeptide X > 0.748 ng/ml (men), 0.738 ng/ml (pre-menopausal women), and
1.351 ng/ml (menopausal women).
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day-care hospital unit, had been infected for several
years and had often experienced disease progression.
Nevertheless, hypovitaminosis D has been shown to be
associated with impaired muscle function in elderly
people [21], and vitamin D supplementation led to
improved muscle function and a decreased risk of falls
in this population.
Last, we also observed a positive association between
SHD and a history of viral hepatitis (positive HCV serology
and “non-cured” HBV infection - i.e. positive HBc without
anti-HBs antibodies), but we did not observe an association
with HCV RNA or HBV DNA. The association with HCV
seropositivity was previously reported in a recent study [15].
These HCV and HBV serological profiles can reflect a wide
range of different realities. However, considering the number
of our patients with known cirrhosis and/or with past or
present chronic hepatitis viral replication, it could be argued
that this relationship may be partially related to disorders in
the hepatic hydroxylation of vitamin D associated with liver
fibrosis [22]. Vitamin D deficiency was also found to be sig-
nificantly associated with active or past smoking, as previ-
ously observed [23].
However, this study may suffer from several limita-
tions, in part due to its cross-sectional design, since no
repetitive measurements of vitamin D levels and inflam-
mation parameters were performed, and thus no causal
relationships can be determined. There was also no con-
trol group without HIV in order to compare the preva-
lence of hypovitaminosis D. In addition, the patients
included may not have been representative, since they
were followed in a French day-care hospital unit. On the
other hand, a high proportion of these patients were
exposed to HAART for a long period of time, which
should strengthen the analysis of the association be-
tween hypovitaminosis D and HAART.
Conclusions
Considering the high prevalence of SHD in our study
and its association with increased inflammation markers,
on the one hand, and with a history of falls and
increased bone catabolism on the other, the results of
our study may have three main implications. First, we
believe that vitamin D levels have to be systematically
and regularly assessed in HIV infected patients. Second,
it may be of interest to take into account not only the
type of antiretroviral therapy but also the residual in-
flammation on HAART in order to assess functional and
fracture risks of HIV infected patients. Third, it is likely
that there is an interest in supplementing hypovitamino-
sis D, at least because it is associated with falls and
increased bone catabolism (as we observed) and thus
fractures (as previously reported). However, whether
increased bone catabolism is a process mainly driven by
hypovitaminosis D rather than by residual inflammation
is yet to be established, as is the best strategy for hypovi-
taminosis D screening and supplementation. It is now
necessary to conduct longitudinal studies to assess not
only the relationship between vitamin D levels and in-
flammation parameters, but also their potential clinical
consequences, as well as the potential benefit of vitamin
D supplementation.
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